Glucose-dependent Insulinotropic Polypeptide Figure 1 ) is a gastrointestinal hormone that is released in response to nutrient intake and stimulates insulin secretion in a glucose-dependent manner 1,2. Although GIP was the first established hormonal component (incretin) of the enteroinsular axis identified, intestinal products of the proglucagon gene, and (GLP-1), were subsequently shown to share its ability of stimulating insulin secretion, and the dual actions of GIP and GLP-1 are widely considered to be the major hormonal contributors to intestinal regulation of pancreatic endocrine function.
There are two major defects in type 2 diabetes that contribute to the hyperglycemia that is characteristic of the disorder: defective responsiveness to glucose and insulin resistance. Current therapies for type 2 diabetics generally involve dietary control plus stimulants of insulin secretion (e.g. sulfonylureas) and/or insulin sensitizers (e.g. metformin, thiazolidinediones). However considerable numbers of patients become resistant to sulfonylurea action and many eventually become insulin-dependent. As a consequence, INTRODUCTION there is increasing interest in developing alternative methods for stimulating endogenous insulin secretion. Among these, there has been a major emphasis on long-acting analogues of GLP-1 3 and, more recently, DP IV-inhibitors, with little interest shown in GIP 4 . The current review focuses on the underlying reasons for this disinterest and attempts to provide a balanced view on the potential for DP IV-resistant analogues of GIP in the treatment of diabetes.
WHY DEVELOP GIP ANALOGUES?
GIP potently stimulates insulin secretion in humans in a glucosedependent manner 2 . Additionally, recent studies have demonstrated that it stimulates beta cell mitogenesis and inhibits apoptosis 5, 6 .
and GLP-1 are equally insulinotropic 7 and conclusions of a much greater potency of GLP-1 can be attributed to comparative studies with batches of synthetic
